146 related articles for article (PubMed ID: 23288484)
1. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Han ES; Wakabayashi M; Leong L
Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Aravantinos G; Pectasides D
J Ovarian Res; 2014; 7():57. PubMed ID: 24864163
[TBL] [Abstract][Full Text] [Related]
3. Targeted anti-vascular therapies for ovarian cancer: current evidence.
Hall M; Gourley C; McNeish I; Ledermann J; Gore M; Jayson G; Perren T; Rustin G; Kaye S
Br J Cancer; 2013 Feb; 108(2):250-8. PubMed ID: 23385789
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
Haunschild CE; Tewari KS
Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study.
Ranieri G; Ferrari C; Di Palo A; Marech I; Porcelli M; Falagario G; Ritrovato F; Ramunni L; Fanelli M; Rubini G; Gadaleta CD
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28684680
[TBL] [Abstract][Full Text] [Related]
6. Targeting the tumour microenvironment in ovarian cancer.
Hansen JM; Coleman RL; Sood AK
Eur J Cancer; 2016 Mar; 56():131-143. PubMed ID: 26849037
[TBL] [Abstract][Full Text] [Related]
7. Role of farletuzumab in epithelial ovarian carcinoma.
Jelovac D; Armstrong DK
Curr Pharm Des; 2012; 18(25):3812-5. PubMed ID: 22591419
[TBL] [Abstract][Full Text] [Related]
8. New ways to successfully target tumor vasculature in ovarian cancer.
Yang X; Shen F; Hu W; Coleman RL; Sood AK
Curr Opin Obstet Gynecol; 2015 Feb; 27(1):58-65. PubMed ID: 25502429
[TBL] [Abstract][Full Text] [Related]
9. Contemporary use of bevacizumab in ovarian cancer.
Miyake TM; Sood AK; Coleman RL
Expert Opin Biol Ther; 2013 Feb; 13(2):283-94. PubMed ID: 23190436
[TBL] [Abstract][Full Text] [Related]
10. Metronomic chemotherapy in ovarian cancer.
Garg V; Kumar L
Cancer Lett; 2023 Nov; 579():216469. PubMed ID: 37923056
[TBL] [Abstract][Full Text] [Related]
11. Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Klempner SJ; Myers AP; Mills GB; Westin SN
Expert Opin Pharmacother; 2013 Nov; 14(16):2171-82. PubMed ID: 23937415
[TBL] [Abstract][Full Text] [Related]
12. New therapeutic agents in ovarian cancer.
Collinson F; Jayson G
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):44-53. PubMed ID: 19125003
[TBL] [Abstract][Full Text] [Related]
13. Recent advancements of antiangiogenic combination therapies in ovarian cancer.
An D; Banerjee S; Lee JM
Cancer Treat Rev; 2021 Jul; 98():102224. PubMed ID: 34051628
[TBL] [Abstract][Full Text] [Related]
14. [Advances in mechanism of traditional Chinese medicine in inhibiting angiogenesis in ovarian cancer].
Tang MY; Ding DN; Xie YY; Shen F; Li J; Liu FY; Han FJ
Zhongguo Zhong Yao Za Zhi; 2023 Dec; 48(24):6572-6581. PubMed ID: 38212017
[TBL] [Abstract][Full Text] [Related]
15. Development of antiangiogenic agents for ovarian cancer.
Collinson FJ; Hall GD; Perren TJ; Jayson GC
Expert Rev Anticancer Ther; 2008 Jan; 8(1):21-32. PubMed ID: 18095880
[TBL] [Abstract][Full Text] [Related]
16. Novel Therapeutics in Ovarian Cancer: Expanding the Toolbox.
Moufarrij S; O'Cearbhaill RE
Curr Oncol; 2023 Dec; 31(1):97-114. PubMed ID: 38248092
[TBL] [Abstract][Full Text] [Related]
17. Mirvetuximab soravtansine superior to chemotherapy in platinum-resistant epithelial ovarian cancer.
Sidaway P
Nat Rev Clin Oncol; 2024 Feb; 21(2):83. PubMed ID: 38114788
[No Abstract] [Full Text] [Related]
18. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
Stone RL; Sood AK; Coleman RL
Lancet Oncol; 2010 May; 11(5):465-75. PubMed ID: 20226736
[TBL] [Abstract][Full Text] [Related]
19. Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer?
García-Martínez E; Redondo A; Piulats JM; Rodríguez A; Casado A
Angiogenesis; 2020 Nov; 23(4):543-557. PubMed ID: 32691290
[TBL] [Abstract][Full Text] [Related]
20. Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer.
Romero D
Nat Rev Clin Oncol; 2024 Jun; 21(6):402. PubMed ID: 38528141
[No Abstract] [Full Text] [Related]
[Next] [New Search]
